Philip Tedeschi

Philip Tedeschi serves as Vice President at Immunovant since July 2020, where responsibilities include leading pre-clinical and non-clinical efforts for IMVT-1402, overseeing the development of clinical protocols, and authoring critical clinical documents. Previously, Tedeschi held roles in prominent organizations such as Pfizer, where contributions focused on oncology research through CRISPR and RNAi technologies, and Adello Biologics and Oncobiologics, concentrating on monoclonal antibody assays in autoimmune and oncology therapeutic areas. Tedeschi's academic background includes a PhD in Pharmacology from Rutgers University and an MS in Molecular Targets and Drug Discovery from The Johns Hopkins University, complemented by a BS in Biology from The College of New Jersey.